You may be part of planned BC class action lawsuit involving cold meds

Article content

A B.C. class action lawsuit has been filed against the manufacturers and retailers of a popular oral cold medicine containing decongestants sold across Canada, which the lawsuit claims are not effective when taken orally. It is said that there is no.

Hardeep Dhaliwal, the lead plaintiff in the case, has been purchasing products containing phenylephrine to treat nasal congestion for the past 20 years, according to a notice of civil action filed in B.C.’s Supreme Court.

Article content

Article content

It lists the medications he regularly purchases: Benylin Extra Strength Cold and Sinus Nighttime, Vicks Dayquil’s Cold and Flu Multiple Symptom Relief Liquid Cap, and Neocitran Cold and a night of sore throat.”

“None of the cold medicines purchased by the plaintiffs provided the nasal decongestant benefits claimed on the product’s label,” the lawsuit states in Canada (with the exception of Quebec, where the same law firm is filing a separate lawsuit). The complaint filed on behalf of the following states: Persons who purchased oral cold medicine containing phenylephrine to treat nasal congestion between December 31, 1989 and the date the lawsuit was certified as a class action.

The company plans to ask the court to refund the amounts consumers paid for these products, as well as award emotional and punitive damages.

The report names Johnson & Johnson, Procter & Gamble, and GlaxoSmithK.C as defendants as manufacturers of these over-the-counter drugs. The cannabis companies that claim millions of dollars in damages were caused by illegal Reserve stores include the province’s Consumer Healthcare, RB Health, retailers Shoppers Drug Mart, Walmart Canada, Amazon.com, London Drugs loses lawsuit against Loblaws.

Article content

Article content

It says phenylephrine is used in medications such as Benylin, Dayquil, Tylenol, Neocitran, Robitucin, and Mucinex.

Slater-Vecchio then claims that the manufacturers and sellers of these products “made false and misleading representations” about how the products worked by claiming they were effective in relieving stuffy noses. ing.a law firm representing plaintiffs in class action lawsuits.

Phenylephrine hydrochloride is a nasal decongestant that is used to temporarily narrow blood vessels in the nose when sprayed onto the membranes of the nasal passages, according to the complaint.

However, when taken orally, “it is first metabolized in the intestines, then absorbed, and transported through the bloodstream to the nasal cavity.”

This delivery method “leads little or no phenylephrine to be absorbed into the bloodstream,” making it “ineffective to exert therapeutic effect,” the report said.

The lawsuit was filed after the U.S. Food and Drug Administration’s independent advisory panel confirmed that “phenylephrine is ineffective when taken orally,” Slater-Vecchio said in a statement.

Article content

The proposed class action lawsuit lists numerous studies showing that oral forms of phenylephrine are unlikely to relieve nasal congestion when taken at the U.S. Food and Drug Administration’s maximum dose of 10 milligrams.

In one study, he said that even four times the oral dose was “not significantly superior to a placebo in reducing nasal congestion.”

As an example, the label for Johnson & Johnson’s Extra Strength Tylenol Sinus Daytime, sold through London Drugs, states that the product contains 5 milligrams of phenylephrine per capsule, according to the complaint. It is said to be a nasal decongestant.

The same label, and other labels for similar products, indicate that cold medicines are effective in decongesting the nasal passages, stating that “cold medicines contain little or no bioavailable phenylephrine. It is said that there was no written statement.

The defendants allege that the money consumers paid “unjustly enriched” them and that consumers “suffered a corresponding deprivation.”

The lawsuit alleges that the defendants knowingly made false statements that were “reckless or knowingly disregarded false or misleading facts” in order to attract “customers to purchase cold medicine from their company.” It alleges that the company violated federal competition law by making misrepresentations.

Article content

It also says the defendants breached B.C.’s Business Practices and Consumer Protection Act.

None of the allegations have been proven in court, and Defendants have not filed a response to the allegations.

Please support our journalism by bookmarking our website: Don’t miss the news you need to know – with VancouverSun.com TheProvince.com Add it to your bookmarks and sign up for our newsletter here.

You can also support our journalism by becoming a digital subscriber. Get unlimited ad-lite access to the Vancouver Sun, Province, National Post and 13 other Canadian news sites for just $14 a month. Please support us by subscribing today: The Vancouver Sun | prefecture.

Article content